Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, +21

New England Journal of Medicine

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, +27

New England Journal of Medicine

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, +16

Journal of Clinical Oncology

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

Mario Sznol, Harriet M. Kluger, Margaret K. Callahan, +17

Journal of Clinical Oncology

ImmunologyImmunotherapeuticsResponse DurationImmunotherapyOncology +17

TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer

Hope S. Rugo, Aditya Bardia, Sara M. Tolaney, +9

Future Oncology

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, +15

npj Breast Cancer

Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer

Véronique Dièras, Robert Weaver, Sara M. Tolaney, +17

Cancer Research

Breast OncologyImmunologyImmunotherapeuticsHigh-grade GliomasNeuro-oncology +18

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

Toni K. Choueiri, Mayer Fishman, Bernard Escudier, +17

Journal of Clinical Oncology

Randomized Clinical TrialImmunologyImmunoeditingImmunotherapeuticsImmunotherapy +18

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

Margaret K. Callahan, Christine E. Horak, Michael A. Curran, +17

Journal of Clinical Oncology

Low AlcImmunologyImmune RegulationPathologyImmunotherapeutics +15

The role of tumor suppressor gene SOX11 in prostate cancer

Zhiyong Yao, Bin Sun, Quan Hong, +5

Tumor Biology